Pfizer Inc. $PFE Shares Sold by Frank Rimerman Advisors LLC

Frank Rimerman Advisors LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 16.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 164,012 shares of the biopharmaceutical company’s stock after selling 32,958 shares during the period. Frank Rimerman Advisors LLC’s holdings in Pfizer were worth $4,084,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Horizon Financial Services LLC increased its position in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares in the last quarter. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer in the third quarter valued at $29,000. Howard Hughes Medical Institute purchased a new stake in shares of Pfizer in the second quarter valued at $30,000. True Wealth Design LLC boosted its stake in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 974 shares during the last quarter. Finally, Darwin Wealth Management LLC purchased a new stake in Pfizer during the 2nd quarter worth about $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $28.08 on Wednesday. The business’s 50-day moving average price is $26.94 and its 200 day moving average price is $25.75. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $28.31. The company has a market capitalization of $159.67 billion, a PE ratio of 20.65 and a beta of 0.47. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the previous year, the business earned $0.63 EPS. The firm’s revenue was down 1.2% on a year-over-year basis. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Royal Bank Of Canada started coverage on shares of Pfizer in a research note on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 target price for the company. Bank of America decreased their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. Finally, UBS Group initiated coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.19.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Fresh real‑world data from Pfizer’s Swedish observational study on Ibrance (palbociclib) is being framed as a positive signal for the drug’s real‑world effectiveness and market durability, which could support oncology revenue expectations. Pfizer’s Swedish Ibrance Study
• Positive Sentiment: Heightened media and retail investor attention around Pfizer’s GLP‑1/weight‑loss pipeline (including coverage noting share strength despite a high‑profile “pass” comment) is boosting sentiment—investors are pricing potential upside from a once‑monthly treatment. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Dividend appeal remains a tailwind for income investors—Pfizer is regularly cited among large caps with attractive dividends, supporting buy‑and‑hold interest. Pfizer – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Retail and institutional attention is elevated (high search/coverage), which can amplify moves but doesn’t guarantee direction — monitor whether flow sustains. Investors Heavily Search Pfizer Inc. (PFE)
• Neutral Sentiment: Broader sector moves (e.g., large deals and AI partnerships at peers) are reshaping investor rotation in healthcare but are not direct Pfizer catalysts; they do, however, affect relative valuation dynamics. Eli Lilly Ramps Up AI Ambitions
• Negative Sentiment: Fundamentals still carry risk: quarterly revenue was slightly down year‑over‑year even as EPS beat estimates, and Pfizer faces stiff competition in the GLP‑1/weight‑loss space from larger early movers—both could cap upside if execution or pricing weakens.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.